ABSTRACT
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune disorder in which cells of the brain and spinal cord are damaged, causing a wide range of neurological symptoms. The most common symptoms of MS exacerbations include paresthesia, motor symptoms, such as muscle cramping or spasticity, spinal cord symptoms, such as bladder, bowel, or sexual dysfunction, and fatigue [1] . As of 2013, more than 2.3 million people worldwide had been diagnosed with MS [2] . On average, annual direct healthcare costs for patients with MS have been shown to be about $24,000 higher compared to the non-MS population [3] . Along with disease-modifying therapies (DMTs), which are designed to reduce inflammation and the risk of subsequent relapses [4, 5] , one of the major drivers of the increased costs in the MS population is expenses related to treating MS exacerbations (relapses) [3] . Medicare data showed that direct costs in patients who experienced relapses were around $17,000 per year, while the costs during remission were about $7300 per year and costs during periods of stabilization were around $4000 per year [3] .
In addition, the expense of treating relapses increases with severity [6] . Compared to a cohort of patients with MS who did not experience any relapses, those who experienced low/moderate severity relapses and high severity relapses had $8269 and $24,180 higher annual incremental direct costs, respectively [6] . Furthermore, MS diagnoses and relapses are associated with significantly reduced health-related quality of life [7, 8] , with patients with MS having about ten fewer quality-adjusted life years (QALYs) compared to patients without MS [9] . MS relapses are usually treated with short courses of high-dose corticosteroids, including intravenous methylprednisolone (IVMP) or high-dose oral prednisone (Deltasone Ò ; Pfizer).
However, around 20% of patients with MS who initiate treatment with high-dose corticosteroids change to other therapies within several months, likely due to poor response [10, 11] or patient preferences [12] .
Alternative therapies include intravenous immunoglobulin (IVIG), which reduces or prevents activation of inflammatory cells and alters antibody responses [13] , plasmapheresis (PMP), which may remove circulating antibodies from blood that cause MS symptoms [14] , and H.P. Acthar Ò Gel (repository corticotropin injection; Acthar; Mallinckrodt), which is thought to have anti-inflammatory properties and works through multiple mechanisms that include indirectly increasing corticosteroid production [15] . Because few studies have focused on patients who received therapies besides IVMP, the purpose of this paper was to describe and generate hypotheses regarding health utilization, outcomes, and costs resulting from the management of MS relapses with Acthar compared to PMP or IVIG among patients with MS who experienced multiple relapses.
METHODS

Study Population and Data Source
We used the Truven Health Analytics MarketScan Separate  eligibility  and  demographics  file  provided  additional information about subjects, such as age, gender, insurance plan type, geographic location, and enrollment status by month.
Because we were interested in evaluating treatments for MS relapses, we limited our study to patients in the database who experienced at least two MS exacerbations between July 1, 2007 to December 31, 2012 for the 12-month analyses or through December 31, 2011 for the 24-month analyses. Patients in both the 12-and 24-month analyses were followed for outcomes until December 31, 2013. We initially identified eligible patients with MS diagnoses (ICD-9-CM code 340.X) who had relapses that were treated with IVMP, the first-line treatment for MS relapse. Patients who were treated for the subsequent relapses were eligible for the study. The index date was the calendar date in which we observed a subsequent treated relapse at least 30 days after the initial relapse with the primary ICD-9-CM diagnosis code for MS along with a claim for one of the non-IVMP relapse treatments: Acthar, IVIG, or PMP (Table 1) . We excluded patients who were not enrolled in their health plans continuously for 6 months prior to and for 12 (for the 12-month analyses) or 24 (for the 24-month analyses) months after the index dates.
Statistical Analysis
We examined associations between receipt of prescriptions for Acthar versus treatment with PMP/IVIG and 1) 12-month cost and utilization outcomes and 2) 24-month cost and utilization outcomes. We initially intended to examine only 24-month costs and utilization but examined 12-month outcomes after discovering that relatively few patients met our exclusion criteria for 24-month outcomes. By definition, all the subjects in the 24-month analyses were also included in the 12-month analyses. We combined patients who received PMP with patients who received IVIG because of small numbers in each individual treatment group and because these are the next line of therapies used after corticosteroids [16, 17] . For the binary outcome of whether patients were readmitted to the hospital within 30 days of discharge, we used logistic regression to calculate odds ratios (ORs) and 95% CIs. For total costs, we used generalized linear regression with a log link and specified the gamma distribution to calculate adjusted means and 95% CIs. We also calculated the absolute differences between the adjusted means, as well as the 95% CI of these differences. SAS for Windows, version 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses.
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation 
RESULTS
For the 12-month analysis, a total of 6603 patients who met our enrollment criteria experienced second relapses; of these, 461 (Table 2) .
Furthermore, patients who received Acthar prescriptions had fewer outpatient services and hospitalizations in the six months prior to the index exacerbation, but filled more prescriptions for all drugs in that time period (Table 2) . When we analyzed patients with MS with 24 months of continuous enrollment (Table S1 in the supplementary material), we found that patients who received Acthar prescriptions were similar to those who received PMP or IVIG in most respects, but patients who received Acthar prescriptions were more likely to have comorbid hemiplegia (P = 0.01) and to have lived in the north central or southern US (P = 0.01). Similar to the 12-month outcomes cohort, patients who 
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Number of rehab and long-term care facilities services Patients who received Acthar prescriptions also had $54,100 lower outpatient costs (95% CI -$80,000 to -$28,000), $74,900 (95% CI $67,000 to $83,000) greater medication costs, but similar average total costs relative to patients who received PMP or IVIG ($5500 higher for Acthar patients; 95% CI -$22,000
to $34,000). Although the costs of medications were increased in the group that received Acthar prescriptions, these costs were offset by 93%
(among the cohort with 12 months of follow-up) and 132% (among the cohort with 24 months of follow-up) by the relative decrease in inpatient and outpatient costs among the group that received Acthar prescriptions.
Following adjustment for significant demographic variables, we found that patients who received Acthar received 3.2 fewer healthcare services overall on average (95% CI -5.2 to -1.1), 0.2 fewer mean hospitalizations (95% CI -0.3 to -0.1), shorter lengths of hospital stay (3.7 days less; 95% CI -4.8 to -1.1), 15 fewer outpatient services (95% CI -20 to -10), and similar total costs (Acthar total costs were $3000 lower; 95% CI -$21,000 to $15,000) compared to patients who received PMP or IVIG (Table 4 ). In addition, following adjustment, we found patients who received Acthar prescriptions had, on average, increased numbers of prescriptions filled (six more prescriptions; 95% CI 4-7) over the 12-month study period. Similar unadjusted and adjusted results were also observed when we examined patients who received Acthar prescriptions compared to patients who received PMP or IVIG with 24 months of continuous enrollment except we did not observe statistically significantly reduced lengths of stay in the hospital (Tables S2 and S3 in the supplementary material).
Estimated proportions of adjusted costs, categorized into medication, outpatient, and hospitalization costs are shown in Fig. 2 and Fig. S2 (in the supplementary material) . Medication costs comprised the greatest proportion of the total costs in Acthar prescription recipients in both the 12-and the 24-month cohorts. For PMP/IVIG recipients, outpatient costs comprised the greatest proportion of the total costs in both cohorts.
DISCUSSION
Compared to patients who received PMP or IVIG for MS exacerbations, adjusted analyses showed that patients who received Acthar prescriptions tended to utilize fewer inpatient and outpatient healthcare services. While patients who received Acthar prescriptions received more prescription medications of any type and had higher proportions of medication costs compared to patients who received PMP or IVIG, total adjusted costs were similar between the two groups. These results remained when we examined patients who were enrolled in our cohort for 24 months continuously.
The mechanism of action of Acthar continues to be explored as current research suggests Acthar may have anti-inflammatory and immunomodulatory properties [15, 20] . Some research has shown that Acthar may benefit patients who do not respond to or tolerate other treatments [21] . While large or long-term trials assessing the use of Acthar for treating MS relapses have not been conducted, the current evidence shows it may have an important role by, for example, minimizing inpatient admissions, which have been associated with MS-related costs [22] .
This study had several limitations. First, because we defined exposure to Acthar using outpatient prescription claims data, it is possible that some patients were subject to misclassification, because they did not actually inject the medication. Furthermore, because this was an observational study and not a randomized controlled trial, we cannot be certain that the differences we observed between patients who did and did not receive Acthar prescriptions were not affected by confounding factors. We corrected for this by adjusting our models for potentially confounding variables, but unmeasured factors might have played a role in the associations that we reported. 
